OSGIN2 (oxidative stress-induced growth inhibitor family member 2) is a monooxygenase involved in cellular responses to oxidative stress 1. While its precise biochemical mechanism remains incompletely defined 1, OSGIN2 functions as a negative regulator of cell growth and proliferation 1. Under oxidative stress conditions, OSGIN2 mediates cell cycle arrest, senescence, and apoptosis 2, and may participate in heavy metal metabolism 3. In the context of cardiovascular disease, OSGIN2 is regulated by the Nrf2 transcription factor in response to cigarette smoke and inflammatory stimuli, where it promotes endothelial cell detachment and dysfunction—mechanisms implicated in plaque erosion, responsible for ~30% of acute coronary syndromes 2. In cancer, OSGIN2 is aberrantly upregulated in gastric and colorectal carcinomas and promotes tumor cell proliferation, cell cycle progression, and autophagy 45. Elevated OSGIN2 expression correlates with poor prognosis in gastric cancer patients and influences tumor-immune infiltration 4. Despite broad phylogenetic conservation and spatiotemporal expression during development, the cellular functions of OSGIN2 remain incompletely connected to its enzymatic properties 1. These findings position OSGIN2 as a potential therapeutic target in both cardiovascular and malignant diseases.